TYRA (Tyra Biosciences) Net Income From Continuing Operations: $-148.57 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TYRA Tyra Biosciences Inc TYRA
33 GF Score
Price $22.03
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Net Income From Continuing Operations?

Tyra Biosciences TYRA -6.41% 33 Net Income From Continuing Operations is $-148.57 Mil as of Jun. 2026. GuruFocus rates TYRA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tyra Biosciences's net income from continuing operations for the three months ended in Jun. 2026 was $-45.56 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-148.57 Mil.

Tyra Biosciences Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences Net Income From Continuing Operations Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial -26.29 -55.33 -69.13 -86.48 -119.95

Tyra Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.10 -29.87 -33.83 -39.31 -45.56
TYRA
33GF Score
Tyra Biosciences Inc TYRA
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-148.57 Mil mean?
Tyra Biosciences (TYRA) has a Net Income From Continuing Operations of $-148.57 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Tyra Biosciences and its competitors.
Is Tyra Biosciences' Net Income From Continuing Operations too high?
Tyra Biosciences' current Net Income From Continuing Operations is $-148.57 Mil. Overall, Tyra Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Net Income From Continuing Operations compare to AVBP and TRAX?
Tyra Biosciences' Net Income From Continuing Operations of $-148.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Tyra Biosciences and its competitors. Tyra Biosciences's current Net Income From Continuing Operations is $-148.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Net Income From Continuing Operations of $-148.57 Mil. The current Net Income From Continuing Operations is $-148.57 Mil. Tyra Biosciences' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Net Income From Continuing Operations is $-148.57 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
33GF Score

Get the complete analysis for TYRA

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.03
Price